Allarity Therapeutics Income Statement (2024-2025) | ALLR

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter) -0.10M-0.43M-0.05M-0.07M-0.06M-0.01M-0.06M-0.06M
Operating items
Research & Development (Quarter) 2.17M1.06M1.02M1.85M1.40M2.32M1.20M1.67M
Selling, General & Administrative (Quarter) 2.07M2.31M1.59M5.47M1.63M1.81M1.31M1.56M
Other Operating Expenses (Quarter) 9.70M
Operating Expenses (Quarter) 4.24M3.37M12.31M7.32M3.04M4.13M2.52M3.24M
Operating Income (Quarter) -4.24M-3.37M-12.31M14.70M-3.04M-4.13M-2.52M-2.92M
EBIT (Quarter) -4.24M-3.37M-12.31M14.70M-3.04M-4.13M-2.52M-2.92M
Non-operating items
Interest & Investment Income (Quarter) 0.05M0.26M0.22M0.22M0.24M0.19M0.15M
Other Non Operating Income (Quarter) 0.08M-0.13M0.12M-0.28M0.14M1.59M-0.42M-0.55M
Non Operating Income (Quarter) 0.39M1.74M0.35M-0.14M0.30M1.81M-0.29M-0.46M
Net income details
EBT (Quarter) -3.85M-1.63M-11.97M8.92M-2.70M-2.32M-2.81M2.30M
Tax Provisions (Quarter) -0.00M-0.38M
Profit After Tax (Quarter) -3.84M-1.63M-11.59M-7.45M-2.73M-2.32M-2.81M-3.37M
Income from Continuing Operations (Quarter) -3.84M-1.63M-11.59M8.92M-2.70M-2.32M-2.81M2.30M
Consolidated Net Income (Quarter) -3.84M-1.63M-11.59M8.92M-2.70M-2.32M-2.81M2.30M
Income towards Parent Company (Quarter) -3.84M-1.63M-11.59M8.92M-2.70M-2.32M-2.81M2.30M
Preferred Dividend Payments (Quarter) 0.23M0.07M0.56M0.26M
Net Income towards Common Stockholders (Quarter) -3.88M-1.67M-12.15M-7.45M-2.73M-2.32M-2.81M-3.37M
Additional items
EPS (Basic) (Quarter) -664.16-3.34-7.719.68-0.25-0.15-0.19-0.21
EPS (Weighted Average and Diluted) (Quarter) -22.14-0.11
Shares Outstanding (Weighted Average) (Quarter) 0.01M0.25M1.58M1.61M11.15M15.54M13.85M14.38M
Shares Outstanding (Diluted Average) (Quarter) 0.18M14.98M
EBITDA (Quarter) -3.82M-1.77M-11.75M-7.11M-3.01M-4.15M-2.65M-2.09M
Interest Expenses (Quarter) 0.10M0.43M0.05M0.07M0.06M0.01M0.06M0.06M
Tax Rate (Quarter) 0.10%3.15%